09:37 AM EST - Aptose Biosciences Inc. : Announced that new clinical data on CG-806, its oral, first-in-class FLT3/BTK cluster selective kinase inhibitor, was presented in a poster presentation today at the 25th Congress of the European Hematology Association, EHA25 Virtual Congress. Early Clinical Findings from a Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin’s Lymphomas (EHA2020 Abstract# EP711) reviewed CG-806 data for eight patients (as of the data cut-off date on May 5, 2020) with relapsed or refractory chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) or non-Hodgkin’s lymphoma in the first in-human Phase 1 a/b, open-label, single arm, multicenter dose-escalation clinical study. Aptose Biosciences Inc.
shares T.APS are trading down $0.18 at $9.04.